Maria Rakowicz

Maria Rakowicz

Auto-generated profile, based on publicly available information

Maria Rakowicz

First Department of Neurology, Institute of Psychiatry and Neurology, Warsaw, Poland

Research Focus & Metrics

Academic Career Length

41Years (1986-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 June 2006 in Neurology
Verified
Journal Article
Closed access
TST Schmitz-Hübsch
T Schmitz-Hübsch
SMS Tezenas Du Montcel
S Tezenas Du Montcel
LBL Baliko
L Baliko
JBJ Berciano
J Berciano
SBS Boesch
S Boesch
RFRoberto Fancellu
Roberto Fancellu
To develop a reliable and valid clinical scale measuring the severity of ataxia. The authors devised the Scale for the Assessment and Rating of Ataxia (SARA) and tested it in two trials of 167 and 119 patients with spinocerebellar ataxia. The mean time to administer SARA in patients was 14.2 +/- 7.5 minutes (range 5 to 40). Interrater reliability was high, with an intraclass coefficient (ICC) of 0.98. Test-retest reliability was high with an ICC of 0.90. Internal consistency was high as indicated by Cronbach's alpha of 0.94. Factorial analysis revealed that the rating results were determined by a single factor. SARA ratings showed a linear relation to global assessments using a visual analogue scale, suggesting linearity of the scale (p < 0.0001, r(2) = 0.98). SARA score increased with the disease stage (p < 0.001) and was closely correlated with the Barthel Index (r = -0.80, p < 0.001) and part IV (functional assessment) of the Unified Huntington's Disease Rating Scale (UHDRS-IV) (r = -0.89, p < 0.0001), whereas it had only a weak correlation with disease duration (r = 0.34, p < 0.0002). The Scale for the Assessment and Rating of Ataxia is a reliable and valid measure of ataxia, making it an appropriate primary outcome measure for clinical trials.

1 November 2015 in The Lancet Neurology
Verified
Journal Article
Closed access
HJHeike Jacobi
Heike Jacobi
SMSophie Tezenas du Montcel
Sophie Tezenas du Montcel
PBPeter Bauer
Peter Bauer
PGPaola Giunti
Paola Giunti
ACArron Cook
Arron Cook
TKThomas Klockgether
Thomas Klockgether

23 September 2008 in Neurology
Verified
Journal Article
Closed access
PDF file
TST. Schmitz-Hübsch
T. Schmitz-Hübsch
MCM. Coudert
M. Coudert
PBP. Bauer
P. Bauer
PGPaola Giunti
Paola Giunti
CGC. Globas
C. Globas
TKT. Klockgether
T. Klockgether
Objective: To identify factors that determine disease severity and clinical phenotype of the most common spinocerebellar ataxias (SCAs), we studied 526 patients with SCA1, SCA2, SCA3. or SCA6. Methods: To measure the severity of ataxia we used the Scale for the Assessment and Rating of Ataxia (SARA). In addition, nonataxia symptoms were assessed with the Inventory of Non-Ataxia Symptoms (INAS). The INAS count denotes the number of nonataxia symptoms in each patient. Results: An analysis of covariance with SARA score as dependent variable and repeat lengths of the expanded and normal allele, age at onset, and disease duration as independent variables led to multivariate models that explained 60.4% of the SARA score variance in SCA1, 45.4% in SCA2, 46.8% in SCA3, and 33.7% in SCA6. In SCA1, SCA2, and SCA3, SARA was mainly determined by repeat length of the expanded allele, age at onset, and disease duration. The only factors determining the SARA score in SCA6 were age at onset and disease duration. The INAS count was 5.0 ± 2.3 in SCA1, 4.6 ± 2.2 in SCA2, 5.2 ± 2.5 in SCA3, and 2.0 ± 1.7 in SCA6. In SCA1, SCA2, and SCA3, SARA score and disease duration were the strongest predictors of the INAS count. In SCA6, only age at onset and disease duration had an effect on the INAS count. Conclusions: Our study suggests that spinocerebellar ataxia (SCA) 1, SCA2, and SCA3 share a number of common biologic properties, whereas SCA6 is distinct in that its phenotype is more determined by age than by disease-related factors.

13 September 2011 in Neurology
Verified
Journal Article
Closed access
PDF file
HJH. Jacobi
H. Jacobi
PBP. Bauer
P. Bauer
PGPaola Giunti
Paola Giunti
RLR. Labrum
R. Labrum
MSM.G. Sweeney
M.G. Sweeney
TKT. Klockgether
T. Klockgether
Objective: To obtain quantitative data on the progression of the most common spinocerebellar ataxias (SCAs) and identify factors that influence their progression, we initiated the EUROSCA natural history study, a multicentric longitudinal cohort study of 526 patients with SCA1, SCA2, SCA3, or SCA6. We report the results of the 1- and 2-year follow-up visits. Methods: As the primary outcome measure we used the Scale for the Assessment and Rating of Ataxia (SARA, 0–40), and as a secondary measure the Inventory of Non-Ataxia Symptoms (INAS, 0–16) count. Results: The annual increase of the SARA score was greatest in SCA1 (2.18 ± 0.17, mean ± SE) followed by SCA3 (1.61 ± 0.12) and SCA2 (1.40 ± 0.11). SARA progression in SCA6 was slowest and nonlinear (first year: 0.35 ± 0.34, second year: 1.44 ± 0.34). Analysis of the INAS count yielded similar results. Larger expanded repeats and earlier age at onset were associated with faster SARA progression in SCA1 and SCA2. In SCA1, repeat length of the expanded allele had a similar effect on INAS progression. In SCA3, SARA progression was influenced by the disease duration at inclusion, and INAS progression was faster in females. Conclusions: Our study gives a comprehensive quantitative account of disease progression in SCA1, SCA2, SCA3, and SCA6 and identifies factors that specifically affect disease progression.

1 July 2013 in The Lancet Neurology
Verified
Journal Article
Closed access
HJHeike Jacobi
Heike Jacobi
KRKathrin Reetz
Kathrin Reetz
SMSophie Tezenas du Montcel
Sophie Tezenas du Montcel
PBPeter Bauer
Peter Bauer
CMCaterina Mariotti
Caterina Mariotti
TKThomas Klockgether
Thomas Klockgether

23 February 2010 in Neurology
Verified
Journal Article
Closed access
PDF file
TST. Schmitz-Hübsch
T. Schmitz-Hübsch
RFR. Fimmers
R. Fimmers
MRM. Rakowicz
M. Rakowicz
RRR. Rola
R. Rola
EZE. Zdzienicka
E. Zdzienicka
TKT. Klockgether
T. Klockgether
Objective: To determine the longitudinal metric properties of recently developed clinical assessment tools in spinocerebellar ataxia (SCA). Methods: A subset of 171 patients from the EUROSCA natural history study cohort (43 SCA1, 61 SCA2, 37 SCA3, and 30 SCA6) were examined after 1 year of follow-up. Score changes and effect size indices were calculated for clinical scales (Scale for the Assessment and Rating of Ataxia [SARA], Inventory of Non-Ataxia Symptoms [INAS]), functional tests (SCA Functional Index [SCAFI] and components), and a patient-based scale for subjective health status (EQ-5D visual analogue scale [EQVAS]). Responsiveness was determined in relation to the patient9s global impression (PGI) of change and reproducibility described as retest reliability for the stable groups and smallest detectable change. Results: Within the 1-year follow-up period, SARA, INAS, and SCAFI but not EQVAS indicated worsening in the whole group and in the groups with subjective (PGI) worsening. SCAFI and its 9-hole pegboard (9HPT) component also deteriorated in the stable groups. Standardized response means were highest for 9HPT (−0.67), SARA (0.50), and SCAFI (−0.48) with accordingly lower sample size estimates of 143, 250, or 275 per group for a 2-arm interventional trial that aims to reduce disease progression by 50%. SARA and EQVAS performed best to distinguish groups classified as worse by PGI. All scales except EQVAS reached the criterion for retest reliability. Conclusion: While both the Scale for the Assessment and Rating of Ataxia and the SCA Functional Index (SCAFI) (and its 9-hole pegboard component) had favorable measurement precision, the clinical relevance of SCAFI and 9-hole pegboard score changes warrants further exploration. The EQ-5D visual analogue scale proved insufficient for longitudinal assessment, but validly reflected patients9 impression of change.